EVRYSDI 5mg tablets medication leaflet

M09AX10 risdiplam • Musculo-skeletal system | Other drugs for disorders of the musculo-skeletal system

Risdiplam is a medication used for the treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older. It works by increasing the production of functional SMN protein, which is essential for the health of motor neurons.

The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor the response to therapy.

Patients should be aware of potential side effects, such as fever, diarrhea, or upper respiratory tract infections. It is important to inform the doctor of any unusual symptoms.

Common side effects include fever, diarrhea, and upper respiratory tract infections. In rare cases, severe reactions such as liver failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about EVRYSDI 5mg

Substance: risdiplam

Commercial code: W71203001

Concentration: 5mg

Pharmaceutical form: tablets

Quantity: 28

Product type: generic

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.

Marketing authorisation

Manufacturer: ROCHE PHARMA AG - GERMANIA

Holder: ROCHE REGISTRATION GMBH - GERMANIA

Number: 1531/2021/02

Shelf life: 3 years

Pharmaceutical forms available for risdiplam

Concentrations available for risdiplam

0.75mg/ml, 5mg